Vanda Pharms Inc Drug Patent Portfolio

Vanda Pharms Inc owns 4 orange book drugs protected by 49 US patents Given below is the list of Vanda Pharms Inc's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11951097 Methods of treating multiple sclerosis 10 Oct, 2042
Active
US11759446 Liquid tasimelteon formulations and methods of use thereof 21 Feb, 2041
Active
US11202770 Liquid tasimelteon formulations and methods of use thereof 11 Dec, 2040
Active
US10220023 Dosing regimen for a selective S1P1 receptor agonist 10 Dec, 2035
Active
US10179119 Method of treatment 29 Aug, 2035
Active
US11266622 Method of treatment 29 Aug, 2035
Active
US10376487 Method of treatment 27 Jul, 2035
Active
US10071977 Highly purifid pharmaceutical grade tasimelteon 12 Feb, 2035
Active
US10829465 Highly purified pharmaceutical grade tasimelteon 12 Feb, 2035
Active
US11566011 Highly purified pharmaceutical grade tasimelteon 12 Feb, 2035
Active
US11760740 Highly purified pharmaceutical grade tasimelteon 12 Feb, 2035
Active
US12049457 Highly purified pharmaceutical grade tasimelteon 12 Feb, 2035
Active
US10610511 Method of treatment 10 Oct, 2034
Active
US11141400 Method of treatment 10 Oct, 2034
Active
US11786502 Method of treatment 10 Oct, 2034
Active
US9730910 Treatment of circadian rhythm disorders 17 May, 2034
Active
US11918556 Treatment of circadian rhythm disorders 07 Apr, 2033
Active
US10149829 Treatment of circadian rhythm disorders 25 Jan, 2033
Active
US10449176 Treatment of circadian rhythm disorders 25 Jan, 2033
Active
US10610510 Treatment of circadian rhythm disorders 25 Jan, 2033
Active
US10945988 Treatment of circadian rhythm disorders 25 Jan, 2033
Active
US10980770 Treatment of circadian rhythm disorders 25 Jan, 2033
Active
US11285129 Treatment of circadian rhythm disorders 25 Jan, 2033
Active
US11633377 Treatment of circadian rhythm disorders 25 Jan, 2033
Active
US11826339 Treatment of circadian rhythm disorders 25 Jan, 2033
Active
US11833130 Treatment of circadian rhythm disorders 25 Jan, 2033
Active
US11850229 Treatment of circadian rhythm disorders 25 Jan, 2033
Active
US11918557 Treatment of circadian rhythm disorders 25 Jan, 2033
Active
US8785492 Treatment of circadian rhythm disorders 25 Jan, 2033
Active
US9060995 Treatment of circadian rhythm disorders 25 Jan, 2033
Active
US9539234 Treatment of circadian rhythm disorders 25 Jan, 2033
Active
US9549913 Treatment of circadian rhythm disorders 25 Jan, 2033
Active
US9855241 Treatment of circadian rhythm disorders 25 Jan, 2033
Active
USRE46604 Treatment of circadian rhythm disorders 25 Jan, 2033
Active
US9062014 Crystalline forms of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-0-tolyl-thiazolidin-4-one 06 May, 2032
Active
US9074254 Method of predicting a predisposition to QT prolongation 28 Dec, 2031
Active
US9074256 Method of predicting a predisposition to QT prolongation 10 Feb, 2031
Active
US9072742 Method of predicting a predisposition to QT prolongation 16 Jan, 2031
Active
US9074255 Method of predicting a predisposition to QT prolongation 17 Dec, 2030
Active
US8999638 Method of treatment based on polymorphisms of the KCNQ1 gene 28 Oct, 2030
Active
US8652776 Prediction of QT prolongation based on SNP genotype 31 Aug, 2030
Active
US9157121 Method of treatment based on polymorphisms of the KCNQ1 gene 05 Apr, 2030
Active
US8586610 Methods for the administration of iloperidone 02 Nov, 2027
Active
US8273779 Thiazolidin 4-one derivatives 17 Dec, 2025
Active
US9138432 Methods for the administration of iloperidone 30 Sep, 2025
Active
US9000018 Thiazolidin-4-one-derivatives 16 Nov, 2024
Active
USRE43728 Thiazolidin-4-one derivatives 16 Nov, 2024
Active
US5856529 Benzofuran and dihydrobenzofuran melatonergic agents 09 Dec, 2022 Expired
USRE39198 Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analgesics 15 Nov, 2016 Expired


Given below is the list of recent legal activities going on the following drug patents of Vanda Pharms Inc.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 10 Jul, 2024 US9539234
Payment of Maintenance Fee, 8th Year, Large Entity 10 Jul, 2024 US9539234
Change in Power of Attorney (May Include Associate POA) 20 Jun, 2024 US8273779
Email Notification 20 Jun, 2024 US8273779
Email Notification 20 Jun, 2024 US9000018
Change in Power of Attorney (May Include Associate POA) 20 Jun, 2024 US9000018
Change in Power of Attorney (May Include Associate POA) 20 Jun, 2024 US9062014
Email Notification 20 Jun, 2024 US9062014
Change in Power of Attorney (May Include Associate POA) 18 Jun, 2024 US11951097
Email Notification 18 Jun, 2024 US11951097
Maintenance Fee Reminder Mailed 13 May, 2024 US8273779
Payment of Maintenance Fee, 4th Year, Large Entity 10 May, 2024 US10829465
Payment of Maintenance Fee, 4th Year, Large Entity 10 May, 2024 US10829465
Post Issue Communication - Certificate of Correction 08 May, 2024 US11951097
Email Notification 01 May, 2024 US11951097


Vanda Pharms Inc's Drug Patent Litigations

Vanda Pharms Inc's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Feb 26, 2016, against patent number US9138432. The petitioner Roxane Laboratories, Inc., challenged the validity of this patent, with Vanda Pharmaceuticals Inc. as the respondent. Click below to track the latest information on how companies are challenging Vanda Pharms Inc's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US10376487 December, 2017 Decision
(13 Feb, 2019)
Vanda Pharmaceuticals, Inc.
US9138432 February, 2016 Terminated-Denied
(30 Aug, 2016)
Vanda Pharmaceuticals Inc. Roxane Laboratories, Inc.


Vanda Pharms Inc Drug Patents' Oppositions Filed in EPO

Vanda Pharms Inc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Oct 21, 2022, by Teva Pharmaceutical Industries Ltd.. This opposition was filed on patent number EP15807916A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP15807916A Oct, 2022 STADA Arzneimittel AG Granted and Under Opposition
EP15807916A Oct, 2022 Teva Pharmaceutical Industries Ltd. Granted and Under Opposition


Vanda Pharms Inc's Family Patents

Vanda Pharms Inc drugs have patent protection in a total of 43 countries. It's US patent count contributes only to 29.8% of its total global patent coverage. 3 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Vanda Pharms Inc Drug List

Given below is the complete list of Vanda Pharms Inc's drugs and the patents protecting them.


1. Fanapt

Fanapt is protected by 10 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9074254 Method of predicting a predisposition to QT prolongation 28 Dec, 2031
(7 years from now)
Active
US9074256 Method of predicting a predisposition to QT prolongation 10 Feb, 2031
(6 years from now)
Active
US9072742 Method of predicting a predisposition to QT prolongation 16 Jan, 2031
(6 years from now)
Active
US9074255 Method of predicting a predisposition to QT prolongation 17 Dec, 2030
(6 years from now)
Active
US8999638 Method of treatment based on polymorphisms of the KCNQ1 gene 28 Oct, 2030
(6 years from now)
Active
US8652776 Prediction of QT prolongation based on SNP genotype 31 Aug, 2030
(5 years from now)
Active
US9157121 Method of treatment based on polymorphisms of the KCNQ1 gene 05 Apr, 2030
(5 years from now)
Active
US8586610 Methods for the administration of iloperidone 02 Nov, 2027
(3 years from now)
Active
US9138432 Methods for the administration of iloperidone 30 Sep, 2025
(11 months from now)
Active
USRE39198 Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analgesics 15 Nov, 2016
(7 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fanapt's drug page


2. Hetlioz

Hetlioz is protected by 32 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11759446 Liquid tasimelteon formulations and methods of use thereof 21 Feb, 2041
(16 years from now)
Active
US10179119 Method of treatment 29 Aug, 2035
(10 years from now)
Active
US11266622 Method of treatment 29 Aug, 2035
(10 years from now)
Active
US10376487 Method of treatment 27 Jul, 2035
(10 years from now)
Active
US10071977 Highly purifid pharmaceutical grade tasimelteon 12 Feb, 2035
(10 years from now)
Active
US10829465 Highly purified pharmaceutical grade tasimelteon 12 Feb, 2035
(10 years from now)
Active
US11566011 Highly purified pharmaceutical grade tasimelteon 12 Feb, 2035
(10 years from now)
Active
US11760740 Highly purified pharmaceutical grade tasimelteon 12 Feb, 2035
(10 years from now)
Active
US12049457 Highly purified pharmaceutical grade tasimelteon 12 Feb, 2035
(10 years from now)
Active
US10610511 Method of treatment 10 Oct, 2034
(10 years from now)
Active
US11141400 Method of treatment 10 Oct, 2034
(10 years from now)
Active
US11786502 Method of treatment 10 Oct, 2034
(10 years from now)
Active
US9730910 Treatment of circadian rhythm disorders 17 May, 2034
(9 years from now)
Active
US11918556 Treatment of circadian rhythm disorders 07 Apr, 2033
(8 years from now)
Active
US10149829 Treatment of circadian rhythm disorders 25 Jan, 2033
(8 years from now)
Active
US10449176 Treatment of circadian rhythm disorders 25 Jan, 2033
(8 years from now)
Active
US10610510 Treatment of circadian rhythm disorders 25 Jan, 2033
(8 years from now)
Active
US10945988 Treatment of circadian rhythm disorders 25 Jan, 2033
(8 years from now)
Active
US10980770 Treatment of circadian rhythm disorders 25 Jan, 2033
(8 years from now)
Active
US11285129 Treatment of circadian rhythm disorders 25 Jan, 2033
(8 years from now)
Active
US11633377 Treatment of circadian rhythm disorders 25 Jan, 2033
(8 years from now)
Active
US11826339 Treatment of circadian rhythm disorders 25 Jan, 2033
(8 years from now)
Active
US11833130 Treatment of circadian rhythm disorders 25 Jan, 2033
(8 years from now)
Active
US11850229 Treatment of circadian rhythm disorders 25 Jan, 2033
(8 years from now)
Active
US11918557 Treatment of circadian rhythm disorders 25 Jan, 2033
(8 years from now)
Active
US8785492 Treatment of circadian rhythm disorders 25 Jan, 2033
(8 years from now)
Active
US9060995 Treatment of circadian rhythm disorders 25 Jan, 2033
(8 years from now)
Active
US9539234 Treatment of circadian rhythm disorders 25 Jan, 2033
(8 years from now)
Active
US9549913 Treatment of circadian rhythm disorders 25 Jan, 2033
(8 years from now)
Active
US9855241 Treatment of circadian rhythm disorders 25 Jan, 2033
(8 years from now)
Active
USRE46604 Treatment of circadian rhythm disorders 25 Jan, 2033
(8 years from now)
Active
US5856529 Benzofuran and dihydrobenzofuran melatonergic agents 09 Dec, 2022
(1 year, 10 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Hetlioz's drug page


3. Hetlioz Lq

Hetlioz Lq is protected by 26 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11759446 Liquid tasimelteon formulations and methods of use thereof 21 Feb, 2041
(16 years from now)
Active
US11202770 Liquid tasimelteon formulations and methods of use thereof 11 Dec, 2040
(16 years from now)
Active
US10179119 Method of treatment 29 Aug, 2035
(10 years from now)
Active
US11266622 Method of treatment 29 Aug, 2035
(10 years from now)
Active
US10376487 Method of treatment 27 Jul, 2035
(10 years from now)
Active
US10071977 Highly purifid pharmaceutical grade tasimelteon 12 Feb, 2035
(10 years from now)
Active
US10829465 Highly purified pharmaceutical grade tasimelteon 12 Feb, 2035
(10 years from now)
Active
US11566011 Highly purified pharmaceutical grade tasimelteon 12 Feb, 2035
(10 years from now)
Active
US11760740 Highly purified pharmaceutical grade tasimelteon 12 Feb, 2035
(10 years from now)
Active
US12049457 Highly purified pharmaceutical grade tasimelteon 12 Feb, 2035
(10 years from now)
Active
US10610511 Method of treatment 10 Oct, 2034
(10 years from now)
Active
US11141400 Method of treatment 10 Oct, 2034
(10 years from now)
Active
US11786502 Method of treatment 10 Oct, 2034
(10 years from now)
Active
US9730910 Treatment of circadian rhythm disorders 17 May, 2034
(9 years from now)
Active
US11918556 Treatment of circadian rhythm disorders 07 Apr, 2033
(8 years from now)
Active
US10149829 Treatment of circadian rhythm disorders 25 Jan, 2033
(8 years from now)
Active
US10610510 Treatment of circadian rhythm disorders 25 Jan, 2033
(8 years from now)
Active
US10980770 Treatment of circadian rhythm disorders 25 Jan, 2033
(8 years from now)
Active
US11285129 Treatment of circadian rhythm disorders 25 Jan, 2033
(8 years from now)
Active
US11633377 Treatment of circadian rhythm disorders 25 Jan, 2033
(8 years from now)
Active
US11826339 Treatment of circadian rhythm disorders 25 Jan, 2033
(8 years from now)
Active
US11833130 Treatment of circadian rhythm disorders 25 Jan, 2033
(8 years from now)
Active
US11850229 Treatment of circadian rhythm disorders 25 Jan, 2033
(8 years from now)
Active
US11918557 Treatment of circadian rhythm disorders 25 Jan, 2033
(8 years from now)
Active
US9539234 Treatment of circadian rhythm disorders 25 Jan, 2033
(8 years from now)
Active
US5856529 Benzofuran and dihydrobenzofuran melatonergic agents 09 Dec, 2022
(1 year, 10 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Hetlioz Lq's drug page


4. Ponvory

Ponvory is protected by 6 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11951097 Methods of treating multiple sclerosis 10 Oct, 2042
(18 years from now)
Active
US10220023 Dosing regimen for a selective S1P1 receptor agonist 10 Dec, 2035
(11 years from now)
Active
US9062014 Crystalline forms of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-0-tolyl-thiazolidin-4-one 06 May, 2032
(7 years from now)
Active
US8273779 Thiazolidin 4-one derivatives 17 Dec, 2025
(1 year, 2 months from now)
Active
US9000018 Thiazolidin-4-one-derivatives 16 Nov, 2024
(a month from now)
Active
USRE43728 Thiazolidin-4-one derivatives 16 Nov, 2024
(a month from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ponvory's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List